Evidence map›Paper›PMID 42387975›Full record

Observational studyNeuropsychopharmacology reports2026

UK Medical Cannabis Registry: A Clinical Outcomes Analysis for Autism Spectrum Disorder.

Arushika Aggarwal, Simon Erridge, Madhur Varadpande, Evonne Clarke, Katy McLachlan, Ross Coomber, Muhammed Asghar, Urmila Bhoskar, Matthieu Crews, Andrea De Angelis and 8 more

Erratum issuedAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Neuropsychopharmacology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Arushika AggarwalMedical Cannabis Research Group, Imperial College London, London, UK.
Simon ErridgeMedical Cannabis Research Group, Imperial College London, London, UK.
Madhur VaradpandeMedical Cannabis Research Group, Imperial College London, London, UK.ORCID https://orcid.org/0009-0005-1365-8682
Evonne ClarkeCuraleaf Clinic, London, UK.
Katy McLachlanCuraleaf Clinic, London, UK.
Ross CoomberCuraleaf Clinic, London, UK.
Muhammed AsgharCuraleaf Clinic, London, UK.
Urmila BhoskarCuraleaf Clinic, London, UK.
Matthieu CrewsCuraleaf Clinic, London, UK.
Andrea De AngelisCuraleaf Clinic, London, UK.
Muhammad ImranCuraleaf Clinic, London, UK.
Fariha KamalCuraleaf Clinic, London, UK.
Laura KorbCuraleaf Clinic, London, UK.
Gracia MwimbaCuraleaf Clinic, London, UK.
Simmi Sachdeva-MohanCuraleaf Clinic, London, UK.
Gabriel ShayaCuraleaf Clinic, London, UK.
James J RuckerCuraleaf Clinic, London, UK.
Mikael H SodergrenMedical Cannabis Research Group, Imperial College London, London, UK.ORCID https://orcid.org/0000-0002-7141-3924

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAutism spectrum disorder (ASD) is a neurodevelopmental disorder associated with distressed behaviors and psychological challenges. This study aims to evaluate the change in health-related quality of life (HRQoL), anxiety, and sleep quality in autistic individuals prescribed cannabis-based medicinal products (CBMPs).

methodThis observational case series analyzed data from the UK Medical Cannabis Registry on autistic adults treated with CBMPs. Demographic and clinical data were collected at baseline, with patient-reported outcome measures assessed up to 18 months. Primary outcomes included changes in anxiety (GAD-7), sleep quality (SQS), and HRQoL (EQ-5D-5L). Secondary outcomes included the incidence of adverse events. Statistical significance was indicated by p < 0.050.

resultsOne-hundred and thirty individuals met the inclusion criteria. GAD-7 (p < 0.001) and SQS (p < 0.001) scores improved from baseline to 18 months. EQ-5D-5L index values showed improvement from baseline (0.43 ± 0.30) to 18 months (0.51 ± 0.32, p < 0.001), and PGIC scores increased from 1 month (5.43 ± 1.49) to 18 months (5.65 ± 1.32, p = 0.013). Twenty-five participants (19.23%) reported a total of 232 (178.46%) adverse events, with most being mild (n = 88; 67.69%) or moderate (n = 99; 76.15%).

conclusionTreatment with CBMPs was associated with improvements in HRQoL, anxiety, and sleep outcomes in autistic patients over an 18-month period. Given the absence of a control group, these findings represent associations rather than proven treatment effects. Further high-quality randomized controlled trials are needed to confirm the long-term efficacy and safety of CBMPs in ASD.

Indexed as

Autism Spectrum DisorderMedical MarijuanaRegistriesAdolescentAdultAnxietyFemaleHumansMaleQuality of LifeSleep QualityTreatment OutcomeUnited KingdomYoung AdultMedical Marijuanaanxietyautism spectrum disordercannabidiolcannabistetrahydrocannabinol

Identifiers

PMID42387975
PMCPMC13323844

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.